Stock Scorecard



Stock Summary for Eledon Pharmaceuticals Inc (ELDN) - $3.90 as of 11/20/2024 4:00:50 PM EST

Total Score

15 out of 30

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for ELDN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ELDN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ELDN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ELDN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ELDN (34 out of 90)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 10

Latest News for for ELDN

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference - Eledon Pharma ( NASDAQ:ELDN ) 9/11/2024 8:05:00 PM
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference 9/11/2024 8:05:00 PM
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results 8/14/2024 9:21:00 PM
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement - Eliem Therapeutics ( NASDAQ:ELYM ) 6/27/2024 8:01:00 PM
Are Medical Stocks Lagging DaVita ( DVA ) This Year? 6/26/2024 1:40:00 PM
ETFs Worth a Look on Russell Indexes' Shake-Up 6/3/2024 3:59:00 PM
Eledon Pharmaceuticals ( ELDN ) Could Find a Support Soon, Here's Why You Should Buy the Stock Now 5/27/2024 1:55:00 PM
Eledon Pharmaceuticals, Inc. ( ELDN ) is a Great Momentum Stock: Should You Buy? 5/22/2024 4:00:00 PM
Eledon Pharmaceuticals ( ELDN ) Moves to Buy: Rationale Behind the Upgrade 5/14/2024 4:00:00 PM
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence - Eledon Pharma ( NASDAQ:ELDN ) 5/7/2024 7:40:00 PM

Financial Details for ELDN

Company Overview

Ticker ELDN
Company Name Eledon Pharmaceuticals Inc
Country USA
Description Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 3.90
Price 4 Years Ago 15.40
Last Day Price Updated 11/20/2024 4:00:50 PM EST
Last Day Volume 423,637
Average Daily Volume 678,677
52-Week High 5.54
52-Week Low 1.11
Last Price to 52 Week Low 251.35%

Valuation Measures

Trailing PE 5.32
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -1.27
Free Cash Flow Ratio 2.98
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 6.53
Total Cash Per Share 1.31
Book Value Per Share Most Recent Quarter 1.85
Price to Book Ratio 3.05
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 59,739,000
Market Capitalization 232,982,100
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 54.16%
Reported EPS 12 Trailing Months 0.73
Reported EPS Past Year -1.72
Reported EPS Prior Year -1.79
Net Income Twelve Trailing Months -1,164,000
Net Income Past Year -40,326,000
Net Income Prior Year -87,966,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 78,200,000
Total Cash Past Year 51,100,000
Total Cash Prior Year 56,409,000
Net Cash Position Most Recent Quarter 78,200,000
Net Cash Position Past Year 51,100,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 7,208,000
Total Stockholder Equity Prior Year 84,183,000
Total Stockholder Equity Most Recent Quarter 76,058,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -35,573,000
Free Cash Flow Per Share Twelve Trailing Months -0.60
Free Cash Flow Past Year 0
Free Cash Flow Prior Year 0

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.35
MACD Signal 0.47
20-Day Bollinger Lower Band 1.55
20-Day Bollinger Middle Band 3.10
20-Day Bollinger Upper Band 4.65
Beta 0.77
RSI 48.21
50-Day SMA 2.45
150-Day SMA 2.52
200-Day SMA 4.10

System

Modified 11/20/2024 11:52:43 PM EST